Sino Biopharmaceutical (DB:SMZ1) - Hisse Senedi Fiyatı, Haberler ve Analizler

SMZ1 Stoklara Genel Bakış

Bir yatırım holding şirketi olan Sino Biopharmaceutical Limited, Çin Halk Cumhuriyeti'nde bir araştırma ve geliştirme ilaç holdingi olarak faaliyet göstermektedir. Daha fazla detay

SMZ1 temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	4/6
Finansal Sağlık	5/6
Temettüler	4/6

Ödüller

Adil değer tahminimizden 72% daha düşük bir oranda işlem görüyor

Kazançların yılda 12.91% oranında artması öngörülüyor

Kazançlar geçen yıl 70.9% oranında arttı

Risk Analizi

Son 3 ayda önemli miktarda içeriden satış gerçekleşti

Kararsız temettü geçmişi

Sino Biopharmaceutical Limited Rakipler

Dermapharm Holding

XTRA:DMP

€2.0b

Merck KGaA

XTRA:MRK

€61.6b

PharmaSGP Holding

XTRA:PSG

€304.6m

Pierrel

DB:2FJ0

€92.8m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Sino Biopharmaceutical
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	HK$0.40
52 Haftanın En Yüksek Seviyesi	HK$0.48
52 Haftanın En Düşük Seviyesi	HK$0.29
Beta	0.69
11 Aylık Değişim	-2.68%
3 Aylık Değişim	11.98%
1 Yıllık Değişim	-9.09%
33 Yıllık Değişim	-38.32%
5 Yıllık Değişim	-48.28%
Halka arzdan bu yana değişim	3,950.22%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	SMZ1	DE Pharmaceuticals	DE Pazar
7D	0%	1.4%	0.8%
1Y	-9.1%	-18.4%	9.1%

Getiri vs. Endüstri: SMZ1 geçen yıl % -18.4 oranında getiri sağlayan German Pharmaceuticals sektörünü aştı.

Getiri vs Piyasa: SMZ1 geçen yıl % 9.1 oranında getiri sağlayan German Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is SMZ1's price volatile compared to industry and market?
SMZ1 volatility
SMZ1 Average Weekly Movement	5.9%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: SMZ1 son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: SMZ1 'nin haftalık oynaklığı ( 6% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2000	24,437	Eric S. Y. Tse	www.sinobiopharm.com

Bir yatırım holding şirketi olan Sino Biopharmaceutical Limited, Çin Halk Cumhuriyeti'nde bir araştırma ve geliştirme ilaç holdingi olarak faaliyet göstermektedir. Üç segmentte faaliyet göstermektedir: Modernize Çin İlaçları ve Kimyasal İlaçlar, Yatırım ve Diğerleri. Şirket, Focus V markası altında anlotinib hidroklorür kapsülleri, Annike markası altında penpulimab enjeksiyonu, Yilishu markası altında efbemalenograstin alfa enjeksiyonu, Anyue markası altında pomalidomid kapsülleri, Anbeisi markası altında bevacizumab enjeksiyonu, Delituo markası altında rituximab enjeksiyonu ve Saituo markası altında enjeksiyon için trastuzumab dahil olmak üzere onkoloji ilaçları sunmaktadır; Tianqing Ganmei markası altında magnezyum izoglisirizinat enjeksiyonu ve Runzhong markası altında entekavir dağılabilir tabletler gibi karaciğer hastalığı ilaçları; ve Tianqing suchang markası altında inhalasyon için budesonid süspansiyonu ve Tianyun markası altında enjeksiyon için kolistimetat sodyum içeren solunum sistemi ilaçları.

Sino Biopharmaceutical Limited Temel Bilgiler Özeti

Sino Biopharmaceutical'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
SMZ1 temel i̇stati̇sti̇kler
Piyasa değeri	€7.26b
Kazançlar(TTM)	€282.70m
Gelir(TTM)	€3.67b

25.7x

F/K Oranı

2.0x

P/S Oranı

SMZ1 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
SMZ1 gelir tablosu (TTM)
Gelir	CN¥27.79b
Gelir Maliyeti	CN¥5.23b
Brüt Kâr	CN¥22.56b
Diğer Giderler	CN¥20.41b
Kazançlar	CN¥2.14b

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	0.12
Brüt Marj	81.16%
Net Kâr Marjı	7.71%
Borç/Özkaynak Oranı	22.6%

SMZ1 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Temettüler

1.8%

Mevcut Temettü Verimi

47%

Ödeme Oranı

SMZ1 Stoklara Genel Bakış

Ödüller

Risk Analizi

Sino Biopharmaceutical Limited Rakipler

XTRA:DMP

€2.0b

XTRA:MRK

€61.6b

XTRA:PSG

€304.6m

DB:2FJ0

€92.8m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Anlotinib Hydrochloride Capsule in Combination with Penpulimab Injection for First-Line Treatment of Advanced Hepatocellular Carcinoma

Sino Biopharmaceutical Limited Announces Approval for Clinical Trials of the Fourth-Generation EGFR Inhibitor "TQB3002" in the United States

Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Anlotinib Hydrochloride Capsules in Combination with Chemotherapy for First-Line Treatment of Advanced Soft Tissue Sarcoma

Key Executive recently sold €5.9m worth of stock

First half 2024 earnings released: EPS: CN¥0.077 (vs CN¥0.06 in 1H 2023)

Sino Biopharmaceutical Limited Announces Phase III Study Results of Culmerciclib in Combination with Fulvestrant for Treatment of HR+/HER2- Advanced Breast Cancer Following Endocrine Treatment Presented At 2024 CSCO

Recent updates

Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Anlotinib Hydrochloride Capsule in Combination with Penpulimab Injection for First-Line Treatment of Advanced Hepatocellular Carcinoma

Sino Biopharmaceutical Limited Announces Approval for Clinical Trials of the Fourth-Generation EGFR Inhibitor "TQB3002" in the United States

Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Anlotinib Hydrochloride Capsules in Combination with Chemotherapy for First-Line Treatment of Advanced Soft Tissue Sarcoma

Key Executive recently sold €5.9m worth of stock

First half 2024 earnings released: EPS: CN¥0.077 (vs CN¥0.06 in 1H 2023)

Sino Biopharmaceutical Limited Announces Phase III Study Results of Culmerciclib in Combination with Fulvestrant for Treatment of HR+/HER2- Advanced Breast Cancer Following Endocrine Treatment Presented At 2024 CSCO

Sino Biopharmaceutical Limited Announces Phase III Study Results of Anlotinib Hydrochloride Capsules in Combination with Penpulimab Injection for First-Line Treatment of Advanced Hepatocellular Cancinoma Was Presented at ESMO 2024

Upcoming dividend of HK$0.03 per share

Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Anlotinib Hydrochloride Capsule in Combination with Penpulimab for First-Line Treatment of Advanced Hepatocellular Carcoma

First half 2024 earnings released: EPS: CN¥0.16 (vs CN¥0.068 in 1H 2023)

Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsule for First-Line Treatment of Advanced Renal Cell Carinoma

Sino Biopharmaceutical Limited to Report Q2, 2024 Results on Aug 13, 2024

Sino Biopharmaceutical Limited Announces Interim Analysis of Phase III Clinical Trial of the Categroy 1 Innovative Drug Culmerciclib Capsule

Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Anlotinib Hydrochloride Capsule in Combination with Chemotherapy for First-Line Treatment of Advanced Soft Tissue Sarcoma

Sino Biopharmaceutical Limited Announces Acceptance of New Drug Application for Categroy 1 Innovative Drug Rovadicitinib Tablet

Sino Biopharmaceutical Limited Receives Approval for Marketing of Liraglutide Injection

Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Innovative Drug Envonalkib Citrate Capsules "Envonalkib (TQ-B3139)"

Sino Biopharmaceutical Limited Announces Approval for Marketing of Gadoteridol Injection

Sino Biopharmaceutical Limited Announces Retirement of Ms. Li Mingqin as Executive Director

Upcoming dividend of HK$0.03 per share

Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for First-Line Treatment of Advanced Renal Cell Carcinoma

Sino Biopharmaceutical Limited Receives Marketing Approval from National Medical Products Administration of China

Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Unecritinib Fumarate Capsules

Full year 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.11 in FY 2022)

Executive Chairwoman of the Board recently bought €695k worth of stock

Sino Biopharmaceutical Limited, Annual General Meeting, Jun 05, 2024

Full year 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.14 in FY 2022)

Sino Biopharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 5 July 2024

Sino Biopharmaceutical Limited Provides Update on Development Progress of Mash Products "Lanifibranor" and "TQA2225"

Sino Biopharmaceutical Limited Announces Latest Results of Phase II Clinical Study of KRAS G12C Inhibitor Garsorasib Tablet

Sino Biopharmaceutical Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Sino Biopharmaceutical Limited Announces Acceptance of the New Indication Application for Marketing of Anlotinib Hydrochloride Capsules and Anti Pd-L1 Benmelstobart

Qingdao Ocean Innovative Products Investment Fund Co., Ltd. and Qingdao Ocean New Kinetic Energy Products Investment Fund (Limited Partnership) agreed to acquire 67% stake in CP Pharmaceutical (Qingdao) Co., Ltd from Sino Biopharmaceutical Limited (SEHK:1177) for CNY 1.8 billion.

Sino Biopharmaceutical Limited Announces Prioritised Evaluation Granted for KRAS G12c Inhibitor Garsorasib Tablet (D-1553)

Now 22% undervalued

Sino Biopharmaceutical Limited Announces Approval of Clinical Trial for Neuropathic Pain

Sino Biopharmaceutical Limited Announces Completion of Patient Enrollment in Phase III Clinical Trial of Anlotinib Combined with Chemotherapy in First-Line Treatment of Advanced Soft Tissue Sarcoma

Sino Biopharmaceutical Limited Announces Phase I Clinical Research Results of Tqh2722

Sino Biopharmaceutical Limited Announces First Dose of the First Batch of Subjects in Phase I Clinical Trial of TQA3038

An unknown buyer acquired Suzhou Tianqing Xingwei Med./Lianyungang Chia Tai Tianqing Med./Zhejia Tianqing Zhongwei Med. from Sino Biopharmaceutical Limited (SEHK:1177) for approximately CNY 150 million.

Sino Biopharmaceutical Limited Announces Application for Phase Ib/II Clinical Trial of Innovative Drug

An unknown buyer acquired 84.2% stake in Shanghai Chia Tai Tongyong Pharmaceutical Co., Ltd. from Sino Biopharmaceutical Limited (SEHK:1177) for CNY 290 million.

Upcoming dividend of HK$0.02 per share at 2.7% yield

Sino Biopharmaceutical Limited Announces IND Application of Innovative Medicine TRD205 (AT2R Antibody) Filed with and Accept by FDA

First half 2023 earnings released: EPS: CN¥0.068 (vs CN¥0.10 in 1H 2022)

Sino Biopharmaceutical Limited Announces Interim Cash Dividend for the Period Ended 30 June 2023, Payable on 27 October 2023

New minor risk - Share price stability

Sino Biopharmaceutical Limited to Report First Half, 2023 Results on Aug 25, 2023

Key Executive recently bought €4.0m worth of stock

Sino Biopharmaceutical Limited Announces Application for Marketing of Loxoprofen Sodium Cataplasms

Upcoming dividend of HK$0.06 per share at 3.0% yield

Sino Biopharmaceutical Limited Announces New Drug Marketing Application for the Category 1 Innovative Anti-Tumor Medicine

Sino Biopharmaceutical Limited Announces Approval for Marketing by National Medical Products Administration of China for F-627 (Efbemalenograstim alfa Injection)

Executive Vice Chairwoman of the Board recently bought €2.4m worth of stock

Full year 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.78 in FY 2021)

Sino Biopharmaceutical Limited Announces Clinical Trial Application of Innovative Medicine "Tqb2103 (Claudin18.2 ADC)" Accepted by Center for Drug Evaluation

Sino Biopharmaceutical Limited Announces Application for Marketing of Category I Innovative Drug Tqb2450 Injection in Combination with Anlotinib Hydrochloride Capsules for the Indication of First-Line Treatment of Small Cell Lung Cancer

Sino Biopharmaceutical Limited Announces the Enrollment of All Patients in Phase III Clinical Trial of "Tqg203"

Less than half of directors are independent